andexanet alfa
Selected indexed studies
- Andexanet Alfa and its Clinical Application. (Heart Int, 2020) [PMID:36277667]
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. (Circulation, 2023) [PMID:36802876]
- Andexanet Alfa: First Global Approval. (Drugs, 2018) [PMID:29926311]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Andexanet Alfa and its Clinical Application. (2020) pubmed
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. (2023) pubmed
- Andexanet Alfa: First Global Approval. (2018) pubmed
- Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. (2019) pubmed
- Andexanet alfa for the reversal of factor Xa inhibitors. (2019) pubmed
- Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent. (2019) pubmed
- Andexanet alfa for the treatment of hemorrhage. (2018) pubmed
- Andexanet Alfa for Reversing Factor Xa Inhibition. (2019) pubmed
- Andexanet alfa for reversal of direct factor Xa inhibitor anticoagulation. (2024) pubmed
- Andexanet Alfa(Archived). (2026) pubmed